Patent classifications
C07D267/20
MCL-1 inhibitors
- Hang Chu ,
- Juan A. Guerrero ,
- Anna E. Hurtley ,
- Tae H. Hwang ,
- Lan Jiang ,
- Darryl Kato ,
- Tetsuya Kobayashi ,
- John E. Knox ,
- Scott E. Lazerwith ,
- Xiaofen LI ,
- David W. Lin ,
- Jonathan W. Medley ,
- Michael L. Mitchell ,
- Devan Naduthambi ,
- Zachary Newby ,
- Neil H. Squires ,
- Vickie H. Tsui ,
- Chandrasekar Venkataramani ,
- William J. Watkins ,
- Hong Yang
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
MCL-1 inhibitors
- Hang Chu ,
- Juan A. Guerrero ,
- Anna E. Hurtley ,
- Tae H. Hwang ,
- Lan Jiang ,
- Darryl Kato ,
- Tetsuya Kobayashi ,
- John E. Knox ,
- Scott E. Lazerwith ,
- Xiaofen LI ,
- David W. Lin ,
- Jonathan W. Medley ,
- Michael L. Mitchell ,
- Devan Naduthambi ,
- Zachary Newby ,
- Neil H. Squires ,
- Vickie H. Tsui ,
- Chandrasekar Venkataramani ,
- William J. Watkins ,
- Hong Yang
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
HEPATITIS B CORE PROTEIN MODULATORS
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
HEPATITIS B CORE PROTEIN MODULATORS
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
HEPATITIS B CORE PROTEIN MODULATORS
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
HEPATITIS B CORE PROTEIN MODULATORS
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
MCL-1 INHIBITORS
- Hang Chu ,
- Juan A. Guerrero ,
- Anna E. Hurtley ,
- Tae H. Hwang ,
- Lan Jiang ,
- Darryl Kato ,
- Tetsuya Kobayashi ,
- John E. Knox ,
- Scott E. Lazerwith ,
- Xiaofen LI ,
- David W. Lin ,
- Jonathan W. Medley ,
- Michael L. Mitchell ,
- Devan Naduthambi ,
- Zachary Newby ,
- Neil H. Squires ,
- Vickie H. Tsui ,
- Chandrasekar Venkataramani ,
- William J. Watkins ,
- Hong Yang
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
MCL-1 INHIBITORS
- Hang Chu ,
- Juan A. Guerrero ,
- Anna E. Hurtley ,
- Tae H. Hwang ,
- Lan Jiang ,
- Darryl Kato ,
- Tetsuya Kobayashi ,
- John E. Knox ,
- Scott E. Lazerwith ,
- Xiaofen LI ,
- David W. Lin ,
- Jonathan W. Medley ,
- Michael L. Mitchell ,
- Devan Naduthambi ,
- Zachary Newby ,
- Neil H. Squires ,
- Vickie H. Tsui ,
- Chandrasekar Venkataramani ,
- William J. Watkins ,
- Hong Yang
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
Hepatitis B core protein modulators
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
Hepatitis B core protein modulators
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.